Trial Profile
A European Randomised Phase 3 Study to Assess the Efficacy and Safety of TOOKAD Soluble for Localised Prostate Cancer Compared to Active Surveillance
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Padeliporfin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Steba Biotech
- 26 Jul 2020 Interim results of 5year analysis of efficacy endpoint, presented at the 35th Congress of the European Association of Urology.
- 12 Sep 2018 Results (n=313) from PCM201, PCM203 and PCM301 studies published in the Journal of Urology
- 20 Jun 2018 Results published in the Steba Biotech Media Release